A skin patch that can deliver vaccines cheaply and effectively has been shown off by its inventor, Prof Mark Kendall, at the TEDGlobal conference in Edinburgh. He said that using a patch rather than a needle could transform disease prevention around the world, and offered hope of usable vaccines for diseases such as malaria.The nanopatch overcomes some of the drawbacks of syringe-given vaccines such as needle phobia and the possibility of contamination caused by dirty needles. Thousands of tiny projections in the patch release the vaccine which is applied into the skin in dry form. He explained: "The projections on the nanopatch work with the skin's immune system. We target these cells that reside just a hair's breadth from the surface of the skin." He went on to say: "It seems that we may have been missing the immune sweet spot which may be in the skin rather than the muscle which is where traditional needles go."
In tests at his laboratory in Queensland University, Brisbane, the nanopatch was used to administer the flu vaccine. Researchers noticed that the immune responses for vaccines administered with the nanopatch were completely different to those given by a traditional syringe. The amount of vaccine needed for it to be effective is also much lower, up to one hundredth of the traditional dose. As well as this, another shortcoming of traditional vaccines is that, because they are liquid, they need to be kept refrigerated between the lab and clinic. However this is not the case with the nanopatch which can be stored at 23°C for up to a year. This is significant because half of vaccines in Africa are not working because refrigeration has failed at some point in the chain.
The news of the nanopatch was given a huge welcome by the British Society for Immunology, Dr Diana Williamson commented: "This approach holds out hope for easy and large-scale vaccination, as it targets a type of immune cell, called the Langerhans cell, that is abundant in the skin. These cells avidly take up the vaccine and are able to kick-start the immune response." However she also warned that one of the potential issues with skin delivery is transit time and ensuring adequate delivery of the vaccine payload. In addition to this there may be issues of tolerability of the patch in some people. However, if these issues can be overcome, the approach does hold out the potential to dispense with conventional needle-based 'intra-muscular' delivery. The nanopatch will soon begin field tests in Papua New Guinea where vaccines are in short supply.
Jack
No comments:
Post a Comment